The average one-year price target for Checkpoint Therapeutics (NASDAQ:CKPT) has been revised to 26.26 / share. This is an increase of 10.04% from the prior estimate of 23.87 dated October 4, 2023. The ...

Checkpoint Therapeutics, Inc. (CKPT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful ...

Checkpoint Therapeutics' Cosibelimab, an anti-PD-L1 antibody, shows promise for treating cSCC, with potential FDA approval by December 2024, making CKPT a speculative "buy." Cosibelimab's dual ...

Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report) is expected to announce its earnings results before the market opens on Friday, March 28th. Analysts expect the company to announce earnings of ...

Checkpoint Therapeutics has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Checkpoint Therapeutics, indicating that it is ...

It might be of some concern to shareholders to see the Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) share price down 14% in the last month. While that might be a setback, it doesn't negate the nice ...

Officially completing its acquisition of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT), Sun Pharmaceutical Industries Ltd. has expanded its immuno-oncology footprint. The deal, announced earlier this ...

WALTHAM, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (CKPT) (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the ...

Checkpoint Therapeutics (NASDAQ:CKPT) just reported results for the second quarter of 2024. Checkpoint Therapeutics reported earnings per share of -18 cents. This was above the analyst estimate for ...